Bispecific Antibodies Across Hematologic Malignancies

CE

Bispecific Antibodies Across Hematologic Malignancies: Nursing Considerations and Skill-Based Training for Clinical Integration

Nurses: 1.00 Nursing contact hour

Released: September 26, 2024

Expiration: April 23, 2025

Beth Faiman
Beth Faiman, PhD, MSN, APN-BC, AOCN, BMTCN, FAAN, FAPO

Pretest

Progress
1 2 3
Course Completed
Please answer the questions below.
1.

In the pivotal phase I/II MajesTEC-1 trial evaluating teclistamab in patients with R/R MM, which of the following was reported?

2.

Your patient with R/R MM is starting treatment with a bispecific antibody, but he is concerned about getting transportation to the treatment facility. Which of the following approved agents would be most convenient for him based on the availability of initial biweekly dosing after completing step-up dosing?

3.

For a patient with DLBCL receiving a CD3 x CD20 bispecific antibody with grade 2 CRS, in addition to supportive care, which of the following would you recommend as the first step for managing this AE?